Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LEMMON WILL MARKET FIRST CARDIZEM SR GENERIC VERSION

Executive Summary

LEMMON WILL MARKET FIRST CARDIZEM SR GENERIC VERSION in the U.S. following FDA's Nov. 30 approval of an ANDA for extended- release diltiazem 60, 90 and 120 mg capsules. The ANDA is held by a French drug delivery company, Prographarm, which developed the product in collaboration with Lemmon and its Israeli parent Teva. Lemmon said it plans to launch the twice-a-day diltiazem formulation "shortly." Cardizem SR sales through the first nine months of 1993 were $97 mil. in the U.S., down 43%, Marion Merrell Dow said. MMD has been shifting patients from the twice-daily product to once-a-day Cardizem CD. MMD has not attempted to preempt the generic market for the twice-daily dosage by introducing a version through its Blue Ridge Labs subsidiary, a strategy it employed when immediate- release diltiazem faced generic competition in late 1992. Teva describes Prographarm as "a privately owned, medium-sized French company specializing in coating technologies and the development and manufacture of sophisticated drug delivery formulations." In 1991, the French firm, located in Chateauneuf en Thymerais, had sales of $6 mil. and 53 employees. Prographarm will manufacture the diltiazem extended-release capsules for Lemmon in France. Another "first generic" approval in late November was Bausch & Lomb's tobramycin ophthalmic solution .3%, equivalent to Alcon's Tobrex. Bausch & Lomb plans to start distributing this month from its Tampa, Florida manufacturing facility. For the month of November, FDA approved a total of 10 ANDA/AADAs. In addition, Novopharm received a tentative ANDA approval for naproxen sodium. Duramed will begin marketing a generic estropipate supplied by Ortho during the week of Dec. 6, the Cincinnati firm announced Nov. 30. Ortho is the manufacturer of Ortho-Est brand of estropipate tablets, approved via an ANDA in 1991. Abbott's Ogen is the innovator, approved for estrogen replacement therapy and prevention of osteoporosis; the osteoporosis indication is protected by Waxman/Hatch exclusivity until 1995. In September, Watson Labs received an ANDA approval for estropipate. For Duramed, the product marks a return to the estrogen replacement therapy market. The company was one of several firms that recalled generic conjugated estrogen products when FDA set new bioequivalence standards. Duramed is working with Schein on a new generic conjugated estrogens product.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS023717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel